A four-lncRNA signature for predicting prognosis of recurrence patients with gastric cancer

Abstract

Purpose This study aimed to develop a multi-long noncoding RNA (lncRNA) signature for the prediction of gastric cancer (GC) based on differential gene expression between recurrence and nonrecurrence patients. Methods By repurposing microarray expression profiles of RNAs from The Cancer Genome Atlas (TCGA), we performed differential expression analysis between recurrence and nonrecurrence patients. A prognostic risk prediction model was constructed based on data from TCGA database, and its reliability was validated using data from Gene Expression Omnibus database. Furthermore, the lncRNA-associated competing endogenous RNA (ceRNA) network was constructed, namely, DIANA-LncBasev2 and starBase database. Results We identified 363 differentially expressed RNAs (317 mRNAs, 18 lncRNAs, and 28 microRNAs [miRNAs]). Principal component analysis showed that the seven-feature lncRNAs screened by support vector machine–recursive feature elimination algorithm was more informative for predicting recurrence of GC in comparison with the eight-feature lncRNAs screened by random forest–out-of-bag algorithm. Four of the seven-feature lncRNAs including LINC00843, SNHG3, C21orf62-AS1, and MIR99AHG were chosen to develop a four-lncRNA risk score model. This risk score model was able to distinguish patients with high and low risk of recurrence, and was tested in two independent validation sets. The ceRNA network of this four-lncRNA signature included 10 miRNAs and 178 mRNAs. The mRNAs significantly related to the Wnt-signaling pathway and relevant biological processes. Conclusion A useful four-lncRNA signature recurrence was established to distinguish GC patients with high and low risk of recurrence. Regulating the relevant miRNAs and Wnt pathway might partly affect GC metastasisby.

Novel histone acetylation-related lncRNA signature for predicting prognosis and tumor microenvironment in esophageal carcinoma

“…Suppression of C21orf62-AS1 led to apoptosis in gastric cancer cells. Furthermore, elevated expression of C21orf62-AS1 was associated with significantly reduced median survival time in gastric cancer patients [ 28 ]. Wang et al [ 29 ] found that abnormal methylation-induced downregulation of lncRNA SSTR5-AS1 promotes the progression and metastasis of laryngeal squamous cell carcinoma.…”

Prognostic Roles of ceRNA Network-Based Signatures in Gastrointestinal Cancers

“…Currently, increasing researches towards ceRNA networks in GICs has not only enhanced our understanding of ceRNA-mediated GICs pathogenesis, but also paved the way for developing novel prognostic biomarkers and therapeutic targets for GICs patients ( 79 ). Indeed, a large number of studies have identified prognostic signatures that predict the OS, metastasis or recurrence of patients with GC, CRC or EC through an integrated analysis of cancer-related ceRNA network ( 41 , 80 , 81 ). However, most of those signatures have not reached the criteria of well-validated effective prognostic models that could improve risk stratification and therapeutic decision making in pre-clinical and clinical practice.…”

“…Therefore, prognostic signatures based on lncRNA/circRNA-mediated ceRNA network are increasingly developed to predict metastasis or recurrence of GC patients, thus helping to optimize clinical treatment and management. For example, Chen et al ( 41 ) successfully established a four-lncRNA signature to predict prognosis and distinguish recurrence risk of GC patients with robust performance.…”